Respiratory Distress syndrome

Complications of prematurity -

Acquired pneumonia  15%

Acquired septicemia  13%

Bronchopulmonary dyspepsia  18%

Special precautions-

Administration- poractant alfa is intended for intratracheal use only.
Administer poractant alfa only by those trained and experienced in the care , resusitication
and stabilization of preterm infants

Dosing precaution -
Transcient adverse effects seen with administration of poractant alfa include bradycardia,
hypotension, endotracheal tube blockage and oxygen desaturation.

These events require stopping poractant alpha administration and taking appropiate
measures to alleviate the conditions. After the patient is stable dosing may proceed with
appropiate monitoring

Prior to administration- corection of acidosis , hypotension, anemia, hypoglycemia and
hypothermia is recommended prior to poracatant alfa administration.

Complication of prematurity - surfactant administration can be expected to reduce severity
of RDS, but will not eliminate the mortality and morbidity associated with other complications
of prematurity

Monitoring- Administration of exogenous surfactants including poractant alpha rapidly
can affect oxygenation, and lung compliance.
Therfore, give infants  receiving poractant alpha  frequent clinical and laboratory  assessment
so oxygen and ventilation  support can be modified to respond to respiratory changes.
oxygenation 

Respiratory Distress syndrome

Dosage-
The initial recommended dose pf poractant alfa is 2.5mg/l/kg birth weight .

Repeat dose- up to 1.25ml/kg borth weight may be administered using the same technique
as used for the first dose.